Overview — Public Health

D2 reaches PA-3 in 2026 through a federal architecture under simultaneous rollback and judicial constraint, a Pennsylvania layer that is mostly operationally aligned with the federal default, and a Philadelphia layer that delivers PDPH's communicable-disease and maternal-child functions inside that federal-state envelope. This page traces three threads through that architecture — federal restructuring partially checked by the courts, where state and local layers have diverged and where they have not, and the structural pressure on the safety-net institutions PA-3 residents most rely on.

Federal restructuring under partial court check

The 2025–2026 window has carried substantial federal restructuring of HHS, CDC, and FDA. FDA reduction-in-force took out approximately 18% of the workforce; aggregate HHS reduction reached roughly 25% counting voluntary separations; most of the FDA RIF took effect on July 14, 2025, after the Supreme Court stayed the Illston preliminary injunction on July 8, 2025. CDC's Immunization Services Division was terminated. CBER lost two successive directors — Peter Marks resigned March 27, 2025; Vinay Prasad subsequently resigned amid political pressure. On August 5, 2025, HHS wound down its mRNA vaccine program, terminating 22 BARDA contracts at approximately $500 million. The Prevention and Public Health Fund — which contributed about 13% of CDC's FY 2024 budget — has been cumulatively rescinded by roughly $11.85 billion across FY 2013–FY 2027, with the Trump FY 2026 budget proposing complete elimination pending Congressional action. On January 5, 2026, a CDC Decision Memo demoted seven childhood vaccines (rotavirus, meningococcal, hep A, hep B, flu, COVID, RSV) from universal recommendation to "shared clinical decision making" status. On April 9, 2026, ACIP's charter was rewritten to broaden scope to "vaccine safety research gaps," "cumulative effects" of childhood vaccines, aluminum adjuvants, and foreign-country schedule comparisons, with non-voting liaison seats added for vaccine-skeptic groups.

Three federal courts are operative checks on the most aggressive elements of this restructuring. In Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (2025), the Supreme Court ruled 6–3 on June 27, 2025 to uphold the ACA § 2713 preventive-services mandate — USPSTF members are inferior officers properly appointed because the HHS Secretary may remove them at will and review their recommendations. USPSTF A/B services — cancer screenings, PrEP, tobacco cessation — remain mandate-protected nationwide. In American Academy of Pediatrics v. Kennedy (D. Mass., 1st Cir.), Judge Brian E. Murphy issued a wide-ranging preliminary injunction on March 16, 2026 that stayed the January 5, 2026 Decision Memo, blocked all 13 of Kennedy's ACIP appointees as failing FACA expertise requirements, invalidated three ACIP votes including the December 2025 hep B birth-dose downgrade, and overturned the May 2025 Secretarial Directive halting COVID-19 vaccine recommendations for pregnant women and healthy children. The pre-January 2026 federal childhood schedule is effectively restored; the reconstituted ACIP membership is blocked, so the body cannot meet. In State of Rhode Island v. Trump (D.R.I.), Judge Melissa DuBose's July 2025 injunction was reaffirmed and narrowed on August 12, 2025 to cover FDA's Center for Tobacco Products, most CDC offices, HHS Office of Head Start, and ASPE — with CDC's Immunization Services Division specifically excluded.

A separate executive-order chain reshaped the environmental-justice architecture that operated across SD5's air, water, lead, and Superfund statutes. Trump EOs 14148 and 14151 (January 20, 2025) revoked EO 14008 (Justice40) and EO 14096 (Biden 2023 EJ); EO 14173 (January 21, 2025) revoked Clinton's 1994 EO 12898. On March 12, 2025, EPA Administrator Lee Zeldin closed the EPA Office of Environmental Justice and External Civil Rights and EJ units in all 10 EPA regions including Region III; EJScreen was taken offline; an OECA memo prohibits enforcement officials from using historical EJScreen data in any enforcement or compliance activity. Selective program continuation runs alongside the rollback: the IRA Medicare Drug Price Negotiation Program's Round 1 took effect January 1, 2026 (10 drugs, with CMS projecting roughly $6 billion in Medicare net Year 1 savings and $1.5 billion in beneficiary out-of-pocket savings); Round 2 prices announced in late November 2025 take effect January 1, 2027; Trump EO 14273 of April 15, 2025 directs program modifications without dismantling.

State and local divergence — and where it isn't

State and local layers are diverging from the federal default in selective areas. State attorneys general have served as the operative litigation channel: a 19-state coalition pursued State of Rhode Island v. Trump before Judge DuBose; a 15-state coalition led by Minnesota AG Keith Ellison filed parallel suit against the January 5, 2026 CDC Decision Memo on February 25, 2026; the AAP-led plaintiffs in Murphy include the Massachusetts Public Health Alliance. Sixteen or more states maintain state-level environmental-justice mapping tools that operate as EJScreen substitutes — Maryland, Massachusetts, and Minnesota among them; Harvard University and Public Environmental Data Partners have produced EJScreen reconstructions. At the state-administered programmatic level, the Pennsylvania Overdose Prevention Program distributed approximately 800,000 naloxone doses and 737,000 fentanyl-and-xylazine test strips in 2025, with approximately 9,500 overdose reversals reported January through September.

Pennsylvania's specific posture is more aligned than diverging. PA continues operating under existing 28 Pa. Code § 23.83 Subchapter C without a divergent state announcement post-Murphy. PA is not a coalition leader on the schedule-litigation track. A PA-specific state EJ mapping tool was not located in the verification window. PA does not have an adult-use cannabis program — which means PA medical cannabis operators under the Medical Marijuana Act of 2016 became § 280E-exempt prospectively for 2026 after the DEA Final Order rescheduling state-licensed medical cannabis to Schedule III on April 22–23, 2026 (Federal Register effective approximately April 28, 2026) and the Treasury / IRS guidance announcement of April 23, 2026, without facing the apportionment-rule complication that affects dual-license operators in adult-use states. The retrospective component of § 280E relief — whether operators can recover prior years of disputed § 280E positions, of which Trulieve alone holds approximately $445 million — was not committed in the Treasury press release.

The Philadelphia layer delivers PDPH's communicable-disease control, maternal-and-child-health services, and substance-use response within the federal-state envelope. AACO Philadelphia EMA administers Ryan White Part A. DBHIDS operates the HealthChoices Behavioral Health single-MCO model through Community Behavioral Health. Prevention Point Philadelphia operates as the city's principal harm-reduction partner. Mayor Parker's Kensington Wellness Court launched in January 2025; through the analytical window, 217 people had been arrested, 72 had accepted treatment, 10 had completed the program, and one of those ten subsequently died of overdose. Approximately two-thirds of those who agreed to treatment have outstanding bench warrants. The Pew 2025 poll on the Mayor's handling of drugs and the opioid crisis rates 28% good or excellent against 39% not very good — a divergence the verified file documents without resolving the magnitude of the policy disagreement underneath.

Safety-net structural pressure and the overdose-mortality bright spot

The institutional capacity reading for PA-3's safety-net institutions is structural pressure manageable in the near term with multi-year exposure to federal Medicaid retrenchment. Temple Health closed FY 2025 with a $22 million operating profit on $3.3 billion in revenue, up 15%; Q1 FY 2026 showed a $15 million operating loss, an improvement from the prior-year quarter. Temple maintains its investment-grade BBB rating. FY 2026 capital spending was trimmed by $10–15 million to $60–65 million, attributed to uncertainty over federal Medicaid funding. Strategic investments continue — eight new oncologists hired at Fox Chase Cancer Center, 34 community physician practitioners, the new Women & Families Hospital in Juniata with operating rooms opened May 2025. Einstein has operated as part of Jefferson Health since the 2021 merger; the standalone "Einstein financial trajectory" framing of earlier project work is anachronistic. The Hahnemann closure of 2019 remains the structural-precedent reference for safety-net system fragility under federalism stress; the current safety-net institutions are stressed but stable in the near term, with multi-year exposure.

Federally Qualified Health Center mandatory funding under § 330 was extended through December 2026 through the 2026 Consolidated Appropriations Act — a short-term extension rather than a multi-year reauthorization despite the advocate push. Companion FY 2026 funding includes $350 million for the National Health Service Corps base and $225 million for Teaching Health Center Graduate Medical Education; Medicare telehealth flexibilities for FQHCs are extended through 2027. The OBBBA Medicaid changes of July 4, 2025 threaten FQHC financial stability over a multi-year horizon — Medicaid is 40% or more of FQHC revenue; community health center operating margins average below -2% with less than 90 days of cash on hand. The HRSA 340B rebate-pilot model launched January 1, 2026 concurrent with IRA Round 1; 65 of 78 active NDCs (about 85%) for 2026 IRA Round 1 drugs have lower 340B ceiling prices than the negotiated Maximum Fair Prices. PA-3's FQHC roster — Philadelphia FIGHT, Puentes de Salud, MANNA, Resources for Human Development, the Family Practice & Counseling Network — sits inside this combined federal-policy-cycle exposure.

The overdose-mortality reading is the domain's clearest substantive bright spot, and it carries an explicit demographic-disparity counterpoint the verification cycle preserved rather than smoothed. Philadelphia overdose deaths peaked at 1,376 in 2022, fell to 1,310 in 2023, fell to 1,045 in 2024 (a 20% year-on-year decline per PDPH), and tracked to 747 as of December 23, 2025 — on pace for the lowest annual count in nearly a decade. Pennsylvania statewide overdose deaths fell from 3,340 in 2024 to 2,178 in preliminary 2025 figures, a 29% decline. The likely causal drivers documented in the verification cycle include expanded long-acting buprenorphine injections, the tripling of Philadelphia buprenorphine prescribers to roughly 1,500 from 2017–2023, supply-chemistry shifts toward medetomidine-plus-xylazine that produce different overdose mechanics (less fatal, more severe withdrawal and wounds), and opioid-settlement funding for naloxone and buprenorphine. The demographic disparity is the structural counterpoint: Pew 2025 polling and prior-year disaggregation indicate the declines have been driven primarily by reductions in White overdose rates while Black rates continued rising through 2024. The aggregate decline is real; the distribution underneath it is not uniform across PA-3 neighborhoods. The bright spot and the gap inside it are simultaneously operative.